Fabrairu 2024: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy Clinician.
According to Emily Littlejohn, DO, MPH, of the Cleveland Clinic, monoclonal antibodies and interferons are two additional potential treatments for systemic lupus erythematosus that have emerged since 2020.
“2020 is what many of us consider the lupus renaissance,” Littlejohn told attendees during the hybrid meeting. “This is a time where, finally, we had many drugs entering the armamentarium very quickly.”
Kuna so karanta: CAR T Cell far in China
According to Littlejohn, there have been a lot of exciting new treatments for SLE since the quick approvals of belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), and anifrolumab (Saphnelo, AstraZeneca). CAR T-cell therapy might be the most exciting of these.
“This is used in the oncology world—we have seen it in [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin’s lymphoma] and mantel cell lymphoma,” Littlejohn said. “The question is: What about in our diseases?”
Littlejohn ya bayyana cewa duk marasa lafiya da suka shiga cikin binciken Jamus wanda ya sanya marasa lafiya biyar tare da haɗin gwiwar gabobin jiki da yawa sun sami damar cimma yanayin da cutar nephritis ta daina. Littlejohn ya kara da cewa sakamakon yana ba da bege, amma maganin ba shi da haɗari.
Kuna so karanta: CAR T Cell far don Multi myeloma a China
"Akwai babban haɗarin ciwon sakin cytokine - ICANS musamman - wanda ke da ban tsoro," in ji ta.
"Ina tsammanin akwai alkawura da yawa a cikin wannan sararin samaniya, kawai la'akari da waɗannan marasa lafiya biyar [wanda aka yi musu magani tare da CAR-T cell far] da kuma yadda suka yi," in ji ta.
Madadin zuwa CAR T-cell far are in development. These include litifilimab (BIIB059, Biogen), interferon—kinoid, obinutuzumab (Gazyva, Genentech) and iberdomide (Bristol Myers Squibb).
Interferon-kinoid ya kasa cimma matsaya a cikin muhimman gwaji, kuma makomarsa "ba ta da tabbas," in ji Littlejohn.
Kuna so karanta: Farashin CAR T Cell a China
"An fara nazarin Litifilimab a cikin marasa lafiya na lupus marasa lafiya, jimlar 132," in ji Littlejohn. "Abin da suka gano shi ne ya hadu da matakin farko tare da raguwar maki CLASI na fata a mako na 16."
Bugu da ƙari, maganin ya yi nasara wajen rage yawan haɗin gwiwa a cikin cututtuka masu aiki, a cewar Littlejohn.
A ƙarshe, obinutuzumab ya sadu da farkon ƙarshensa a cikin marasa lafiya da lupus nephritis, in ji Littlejohn.
